# Mechanism of Genome Editing Tools and Their Application on Genetic Inheritance Disorders

## TL;DR

This paper reviews genome editing tools like CRISPR and their use in treating genetic disorders, highlighting new approaches to improve treatment efficiency.

## Contribution

The paper introduces new approaches in gene therapy to enhance treatment efficiency for genetic disorders.

## Key findings

- CRISPR-based tools have evolved to include base and prime editors for more precise gene editing.
- Adeno-associated virus (AAV) vectors are widely used in gene therapy but have limitations like limited capacity and immunogenicity.
- Different genetic disorders may require different genome editing approaches due to variations in single-base pair variants.

## Abstract

In the fields of medicine and bioscience, gene editing is increasingly recognized as a promising therapeutic approach for treating pathogenic variants in humans and other living organisms. With advancements in technology and knowledge, it is now understood that most genetic defects are caused by single-base pair variants. The ability to substitute genes using genome editing tools enables scientists and doctors to cure genetic diseases and disorders. Starting with CRISPR (clustered regularly interspaced short palindromic repeats)/Cas, the technology has evolved to become more efficient and safer, leading to the development of base and prime editors. Furthermore, various approaches are used to treat genetic disorders such as hemophilia, cystic fibrosis, and Duchenne muscular dystrophy. As previously mentioned, most genetic defects leading to specific diseases are caused by single-base pair variants, which can occur at many locations in corresponding gene, potentially causing the same disease. This means that, even when using the same genome editing tool, results in terms of editing efficiency or treatment effectiveness may differ. Therefore, different approaches may need to be applied to different types of diseases. Prevalently, due to the safety of adeno-associated virus (AAV) vectors in gene therapy, most clinical trials of gene therapy are based on AAV delivery methods. However, despite their safety and nonintegration into the host genome, their limitations, such as confined capacity, dosage-dependent viral toxicity, and immunogenicity, necessitate the development of new approaches to enhance treatment effects. This review provides the structure and function of each CRISPR-based gene editing tool and focuses on introducing new approaches in gene therapy associated with improving treatment efficiency.